Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Coronavirus in China. Novel coronavirus (2019-nCoV), people in white medical face mask. Concept of coronavirus quarantine vector illustration. Seamless pattern.
Much of Pfizer's Q2 call revolved around its COVID-19 vaccine • Source: Shutterstock

Pfizer Inc. sees a long-term commercial opportunity for a COVID-19 vaccine, one that will change as the global health crisis moves beyond the pandemic phase. Much of the company's second quarter sales and earnings call on 28 July was dedicated to the high-profile vaccine, from the development timeline, potential safety and efficacy issues and ultimately, the commercial opportunity for Pfizer.

Pfizer, with partner BioNTech SE, is a frontrunner in the race to develop a vaccine against SARS-CoV-2, with the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.